zamristobart
Generic: Zamristobart
zamristobart: 2 clinical trials tracked.
zamristobart evidence translation
What we can confirm
2 tracked trials
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about zamristobart, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (2)
Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors
Primary endpoint: Safety and adverse events (AEs)
Interventionalopen40 targetStarted 2025-07Completion 2030-091 site · United StatesM.D. Anderson Cancer Center
A Phase 1/2, Dose Escalation, Dose Expansion, and Dose Optimization Study of the Safety, Tolerability, and Anti-tumor Activity of SAR444881 Administered Alone and in Combination With Pembrolizumab, Cetuximab and/or Chemotherapy in Participants With Advanced Solid Tumors
Primary endpoint: Part 1: Incidence of treatment-emergent adverse events (TEAEs) dose limiting toxicities (DLT)
Interventionalopen125 targetStarted 2021-04Completion 2025-0718 sites · Canada, Israel, United Kingdom, United StatesSanofi